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Summary  Over  the  past  years,  natriuretic  peptides  have  been  recognised  not  only  as  impor-
tant contributors  to  cardiovascular  regulation  but  also  as  valuable  markers  in  overt  cardiac
disease, including  heart  failure  or  coronary  disease.  More  recently,  these  markers  have  shown
their ability  to  detect  preclinical  cardiac  alterations  in  different  settings.  In  this  respect,
natriuretic  peptides  offer  a  new  perspective  for  risk  stratiﬁcation  in  hypertension.  They  are  cor-
related to  various  features  of  cardiac  remodelling  provoked  by  hypertension.  They  also  depend
on vascular  properties,  including  blood  pressure  level  and  aortic  stiffness.  In  addition  to  being
integrative  markers  of  cardiovascular  alterations,  several  studies  have  shown  their  value  in  pre-
dicting all-cause  mortality  or  cardiovascular  mortality  and  morbidity  in  the  general  population.
At least  three  consistent  studies  are  now  available  in  hypertension  also  showing  this  prognostic
value. This  performance,  together  with  the  ease  of  measurement,  low  cost  and  widespread
availability,  should  prompt  the  wide  use  of  natriuretic  peptides  for  risk  stratiﬁcation  in  hyper-
tension,  at  least  in  patients  with  normal  electrocardiography,  but  also  in  most  hypertensive
patients.
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Résumé  Ces  dernières  années,  l’importance  des  peptides  natriurétiques  a  été  reconnue  non
seulement  pour  leur  contribution  à  la  régulation  cardiovasculaire  mais  surtout  comme  des
marqueurs  dans  l’insufﬁsance  cardiaque  et  la  maladie  coronaire.  Plus  récemment,  ces  mar-
queurs ont  été  utilisés  pour  détecter  des  atteintes  cardiaques  infracliniques.  Dans  ce  contexte,
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ils  offrent  de  nouvelles  perspectives  pour  la  stratiﬁcation  du  risque  dans  l’hypertension.  Leurs
taux plasmatiques  sont  corrélés  à  différents  aspects  du  remodelage  cardiaque  induit  par
l’hypertension.  Ils  dépendent  également  des  propriétés  vasculaires,  incluant  la  pression  et  la
rigidité aortique,  et  de  la  fonction  rénale.  Au-delà  de  l’aspect  de  marqueurs  intégratifs  des  dys-
fonctionnements  cardiovasculaires,  plusieurs  études  ont  récemment  montré  leur  valeur  dans
la prédiction  de  la  mortalité  globale  ou  la  morbi-mortalité  cardiovasculaire  dans  la  population
générale.  Au  moins  trois  études  sont  maintenant  disponibles  confortant  cette  valeur  pronos-
tique dans  l’hypertension  artérielle.  Cette  performance  associée  à  la  facilité  de  la  mesure,  au
coût modéré  et  à  sa  large  disponibilité  devraient  accélérer  l’utilisation  du  dosage  des  peptides
natriurétiques  pour  la  stratiﬁcation  du  risque  dans  l’hypertension  artérielle,  au  moins  chez  les
patients avec  un  ECG  normal  si  ne  n’est  chez  la  plupart  des  hypertendus.
© 2011  Elsevier  Masson  SAS.  Tous  droits  réservés.
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NP atrial  natriuretic  peptide
NP brain  natriuretic  peptide
CG electrocardiography
VH left  ventricular  hypertrophy
T N-terminal
ntroduction
n  response  to  volume  expansion  and  pressure  load,  ven-
ricular  myocytes  release  cardiac  hormones  with  potent
atriuretic  effect  associated  with  vasodilation  and  strong
ntiﬁbrotic  effects.  Theses  hormones  oppose  the  sympa-
hetic  and  renin-angiotensin-aldosterone  system  in  blood
ressure  control  and  cardiovascular  remodelling  [1]  (Fig.  1).
he  two  main  peptides,  ANP  and  BNP,  stem  from  differ-
nt  genes  and  have  speciﬁc  spatiotemporal  expression;  they
re  differentially  expressed  in  the  heart  [2].  Both  hor-
ones  are  small  cyclic  peptides  with  very  similar  amino  acid
ompositions,  acting  on  the  same  membrane  receptor  (natri-
retic  peptide  receptor-A),  which  is  a  membrane  guanylate
yclase.  Both  are  generated  by  proteolytic  cleavage  from
 prohormone,  which  gives  rise  to  an  equimolar  amount
f  the  remnant  peptide,  NT-ANP  or  NT-BNP,  and  of  each
ctive  ANP  or  BNP  hormone  (Fig.  2).  They  are  each  of  great
nterest,  both  in  terms  of  pathophysiology  and  as  poten-
ial  drug  targets  [3,4]. The  availability  of  reliable  plasma
ssays  for  the  different  players  has  identiﬁed  BNP,  together
ith  its  amino-terminal  fragment  (NT-proBNP),  as  the  most
romising  markers  for  cardiac  diseases.  Over  the  past  years,
s  a  result  of  a  tremendous  amount  of  work  in  this  ﬁeld,
hese  hormones  have  profoundly  changed  the  management
f  heart  failure  and  are  now  recommended  for  diagnosis,
rognostic  stratiﬁcation,  and  treatment  adjustment.
More  recently,  the  potential  of  these  markers  in  hyper-
ension  has  been  questioned.  Why  so?  Reasons  are  numerous,
anging  from  the  physiopathology  of  hypertension  where
salt  sensitivity’  is  a  key  mechanism  in  hypertension  and  has
o  be  related  to  the  natriuretic  peptide  system,  to  detection
f  hypertension  consequences  in  terms  of  target  organ  dam-
ge.  In  hypertension,  detection  of  cardiac  damage  is  critical
or  risk  stratiﬁcation,  as  emphasized  by  most  guidelines  [5].
c
c
d
lhis  is  usually  done  by  searching  for  LVH  and  more  generally
y  identifying  pathological  cardiac  remodelling.  The  ideal
arker  for  screening  should  be  easy  to  measure,  widely
vailable,  reproducible,  correlated  with  cardiac  status  and,
ost  of  all,  correlated  with  outcomes.
ECG,  which  is  recommended  by  most  guidelines,  appar-
ntly  ﬁts  all  these  requirements,  except  that  it  is  rarely
erformed  in  clinical  practice  [6]  because  of  either  the
ack  of  ECG  devices  or  insufﬁcient  skills  in  the  interpreta-
ion  of  ECG  recordings.  Echocardiography,  which  remains  the
gold  standard’  in  clinical  practice,  suffers  from  a  lack  of
vailability  for  all  hypertensive  patients  and  from  its  cost,
aking  this  investigation  not  indicated  for  risk  stratiﬁcation
f  hypertensive  patients  in  general.  Thus,  there  is  still  room
or  new  cardiac  markers  to  be  used  for  risk  stratiﬁcation.
hy are natriuretic peptides of potential
nterest  in hypertension?
s  mentioned  above,  some  prerequisites  should  be  met
efore  a  marker  is  considered  as  potentially  interesting  for
isk  stratiﬁcation  in  hypertension.  In  this  respect,  assays  of
atriuretic  peptides  in  plasma  are  easily  available,  inde-
endent  of  the  operator’s  skills,  and  their  cost  (D  22.95  in
rance)  compares  with  the  cost  of  ECG.  We  have  recently
ooked  at  the  distribution  of  plasma  NT-proBNP  concentra-
ions  in  a  large  cohort  of  hypertensive  patients;  while  the
lasma  concentrations  were,  on  average,  much  lower  than  in
vert  cardiac  disease  —  namely,  heart  failure  —  they  covered
 wide  range,  from  undetectable  values  to  fairly  high  ones
7].  Despite  this  wide  interindividual  variability,  the  intrapa-
ient  reproducibility  of  NT-proBNP  measured  at  arrival  in  the
ospital  (ambulatory)  and  in  decubitus  after  one  night’s  rest
n  hospital  was  very  satisfactory,  with  a  coefﬁcient  of  vari-
tion  around  5%.  The  fact  that  expression  and  secretion  of
NP  by  ventricular  myocytes  is  a  landmark  of  cardiac  remod-
lling  is,  of  course,  of  particular  interest  in  hypertension.
n  this  context,  NT-proBNP  may  be  more  suitable  than  BNP
ecause  of  its  longer  half-life,  lower  intraindividual  variabil-
ty,  and  better  ability  to  detect  subtle  preclinical  cardiac
hanges  [8].  The  secretion  of  natriuretic  peptides  mainly
orrelates  with  left  ventricular  wall  stress,  either  systolic  or
iastolic  [9],  which  is  a  complex  interplay  between  pressure,
eft  ventricular  diameter,  and  wall  thickness.  Consistently,
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Figure 1. Physiological actions of natriuretic peptides in different tissues contribute to decreased venous return and decreased heart
stress in a classical negative regulatory loop. ACTH: adrenocorticotrophic hormone; ADH: antidiuretic hormone; ANP: atrial natriuretic
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in  essential  hypertensive  patients  with  LVH.  Furthermore,peptide; BNP: B-type natriuretic peptide; GFR: glomerular ﬁltration
most  studies  have  found  an  increased  concentration  of
plasma  natriuretic  peptides  associated  with  LVH;  NT-proBNP
was  also  found  to  be  related  to  systolic  dysfunction  [8],  dias-
tolic  dysfunction,  and  increased  ﬁlling  pressure  [10], while
BNP  is  secreted  in  response  to  myocardial  ischaemia  [11].
Additional  non-cardiac  factors  inﬂuence  natriuretic  peptide
release.  This  is  the  case  with  ventricular  afterload,  par-
ticularly  blood  pressure  [12]  and  aortic  stiffness  [13,14].
Finally,  plasma  natriuretic  peptide  concentrations  are  raised
with  renal  failure  [15,16],  as  a  result  of  both  insufﬁcient
clearance  and  increased  blood  volume  or  an  impaired  cardio-
vascular  system  (Fig.  3).  In  this  respect,  natriuretic  peptides
act  as  integrative  markers  of  cardiac,  vascular,  and  even
renal  status,  i.e.  three  major  targets  of  elevated  blood  pres-
sure.  Indeed,  it  has  been  suggested  that  natriuretic  peptides
represent  markers  of  cardiorenal  distress  [17].
Evidence available in hypertensionIn  animal  models,  the  increased  cardiac  expression  and
secretion  of  natriuretic  peptides  is  a  landmark  of  cardiac
B
t
u; NT: N-terminal.
verload  and  associated  remodelling.  In  a  previous  work,
e  showed  that,  in  hypertensive  patients,  the  relationship
etween  left  ventricular  mass  and  NT-proBNP  was  strong
nough  to  propose  this  marker  as  a test  for  LVH  with  a  rea-
onable  diagnostic  performance  (area  under  the  curve  0.816
conﬁdence  interval  0.72—0.91])  [12]. By  using  a receiver
perating  characteristic  (ROC)  regression  model,  we  demon-
trated  that  this  performance  was  independent  of  several
onfounders,  including  age,  systolic  blood  pressure,  and  cre-
tinine  clearance,  while  the  effect  of  body  mass  index  was  of
orderline  signiﬁcance.  Of  interest  was  the  fact  that  the  per-
ormance  of  the  test  was  statistically  better  in  women  than
n  men.  The  value  of  natriuretic  peptides  for  the  diagnosis
f  LVH  has  been  variably  conﬁrmed  by  other  teams.  Moril-
as  et  al.  found  a  very  similar  performance  compared  with
agnetic  resonance  imaging  [18], as  did  a second  report
19]  when  C-reactive  protein  was  included.  Nishikimi  et  al.
howed  that  plasma  ANP  and  BNP  concentrations  increasedNP  secretion  was  augmented  to  a  greater  extent  in  concen-
ric  hypertrophy.  They  suggested  that  these  markers  may  be
seful  for  the  detection  of  concentric  LVH  in  patients  with
406  G.  Bricca,  P.  Lantelme
Figure 2. Metabolic aspects of BNP and NT-proBNP secretion in blood. Contrary to ANP, which is stored in secretory granules and released
upon stretch in atria myocytes, BNP is constitutively secreted in an equimolar ratio with NT-proBNP. ProBNP, the complete form of the
precursor, can also be directly released from cardiomyocytes into the circulation. While the metabolism of BNP via a set of proteases is
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23.0  and  39.7  pg/mL.  More  recently,  in  a  community-basedelatively well characterized, the mechanisms of NT-proBNP metab
atriuretic peptide; NT: N-terminal.
ssential  hypertension  [20]. On  the  contrary,  Vasan  et  al.
21]  and  Nakamura  et  al.  [22]  showed  that  BNP  was  of  lim-
ted  value  for  the  detection  of  LVH.  These  discrepancies  can
robably  be  explained  by  the  fact  that  natriuretic  peptides
ot  only  depend  on  left  ventricular  mass  but  also  on  diastolic
unction,  as  previously  mentioned.  They  may  also  be  inﬂu-
nced  by  mild  systolic  impairment  assessed,  for  example,
y  midwall  shortening  fraction  (unpublished  personal  obser-
ation).  Several  reports  have  addressed  the  value  of  these
arkers  for  detecting  preclinical  cardiac  abnormalities.  The
bility  of  BNP  as  a  screening  test  for  preclinical  systolic  or
iastolic  dysfunction  has  been  found  to  be  either  good  [23]
r  suboptimal  [24]. Because  of  the  various  possible  combi-
ations  of  mass  and  diastolic/systolic  dysfunction,  it  is  not
urprising  that  the  relationship  of  natriuretic  peptides  with
ne  of  these  variables  may  vary  and  that  an  elevation  of
hese  markers  does  not  always  reﬂect  the  same  feature  of
ardiac  remodelling.  Far  from  being  a  limitation,  this  char-
cteristic  may  be  used  in  hypertension  to  provide  a  tool  that
an  detect  any  form  of  cardiac  injury.  This  usefulness  may
ven  go  beyond  cardiac  remodelling,  as  high  blood  pres-
ure  and  aortic  stiffness  per  se  are  also  able  to  raise  plasma
atriuretic  peptides  [12].
rognostic data in hypertensionn  increasing  number  of  reports  have  conﬁrmed  the
alue  of  natriuretic  peptides  as  predictors  of  outcomes
n  patients  free  from  heart  failure,  on  top  of  classical
c
a
c are less well-deﬁned. ANP: atrial natriuretic peptide; BNP: B-type
ramingham-type  risk  factors.  In  a  subset  of  270  hyper-
ensives  from  the  general  population  with  no  left
entricular  dysfunction,  Pedersen  et  al.  showed  that  NT-
roBNP  was  predictive  of  a  composite  endpoint  of  death,
troke/transient  ischaemic  attack  or  myocardial  infarction
25];  this  was  independent  of  traditional  cardiovascular
isk  factors.  The  median  NT-proBNP  concentration  in  the
tudy  population  was  103.8  pg/mL;  this  threshold  was  asso-
iated  with  a  marked  increased  risk  for  those  patients  with
oncentrations  above  it.  Olsen  et  al.  [26,27]  showed  that
T-proBNP  had  a  signiﬁcant  prognostic  value  in  two  com-
lementary  analyses  of  the  LIFE  substudy,  i.e.  in  highly
evere  hypertensive  subjects  with  electrical  LVH.  In  the  lat-
er  report,  NT-proBNP  predicted  a  composite  endpoint  of
ardiovascular  death,  non-fatal  stroke  or  non-fatal  myocar-
ial  infarction  after  adjustment  for  traditional  risk  factors,
rinary  albumin/creatinine  ratio,  and  history  of  diabetes  or
ardiovascular  disease.  In  this  case,  the  proposed  concen-
ration  threshold  was  around  170  pg/mL;  of  note,  all  these
atients  had  electrical  LVH.  McKie  et  al.  showed  in  a
ommunity-based  cohort  of  2042  subjects  free  from  heart
r  renal  failure,  29%  of  whom  were  hypertensives,  that
NP  and  NT-proBNP  were  independent  predictors  of  all-
ause  death  [28]. Again,  a  similar  NT-proBNP  concentration
hreshold  of  109  pg/mL  was  of  prognostic  value.  Depend-
ng  on  the  technique  used,  the  cutoff  for  BNP  lay  betweenohort  of  5063  participants  free  of  cardiovascular  disease
nd  aged  greater  or  equal  to  55  years,  circulating  NT-proBNP
oncentrations  appeared  predictive  of  a  ﬁrst  major  fatal
Natriuretic  peptides  and  hypertension  407
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N-terminal.
or  non-fatal  cardiovascular  event.  When  analysed  in  more
detail,  NT-proBNP  was  predictive  of  coronary  heart  disease,
heart  failure,  and  ischaemic  stroke.  This  risk  prediction  was
veriﬁed  beyond  classical  risk  factors  [29]. In  this  study,  the
proposed  thresholds  were  much  lower  than  the  aforemen-
tioned  ones,  probably  because  the  population  came  from
the  general  population  with  less  hypertensive  patients.
The  last  contribution  in  this  ﬁeld  was  made  by  our
group.  In  684  patients  with  hypertension  of  varying  severi-
ties  followed  for  an  average  duration  of  5.7  years,  NT-proBNP
appeared  again  to  be  signiﬁcantly  associated  with  all-cause
death  [7]  (Fig.  4).  This  predictive  value  was  observed  on
top  of  classical  risk  factors,  and  was  also  independent  of
renal  function,  and  ECG  LVH  estimated  either  by  the  Sokolov
index  or  by  the  amplitude  of  the  R  wave  in  the  aVL  lead.
Finally,  even  the  inclusion  of  ambulatory  blood  pressure
in  the  model  did  not  inﬂuence  the  prognostic  value  of
NT-proBNP,  which  in  all  cases  remained  the  second  most
predictive  variable  after  age.  This  study  conﬁrmed  for  the
ﬁrst  time  in  a  cohort  of  hypertensive  patients  who  were
fairly  representative  of  everyday  hypertensive  patients,  the
value  of  this  marker,  which  had  already  been  documented
in  more  severe  hypertensive  patients  or  in  the  general
population,  beyond  traditional  risk  factors.  Interestingly,
t
v
N
trdiovascular risk assessment. BNP: B-type natriuretic peptide; NT:
 concentration  threshold  of  around  130  pg/mL  was  again
ssociated  with  a  substantial  increase  of  risk  and  could  be
roposed  as  an  acceptable  cutoff.
ffect of treatment on natriuretic
eptides
owadays,  most  hypertensive  patients  are  treated  with  a
ariety  of  antihypertensive  drugs  including  diuretics,  beta-
lockers,  and  renin-angiotensin  system  blockers.  This  raises
wo  important  points:  (1)  the  extent  to  which  the  prognostic
alue  is  affected  by  the  treatment;  (2)  whether  the  change
n  NT-proBNP  can  be  used  as  a  target  for  therapy,  as  in  heart
ailure  patients.
In our  recently  published  study,  the  presence  of  a  treat-
ent  did  not  interact  with  the  prognostic  value  of  NT-proBNP
ut  we  were  unable  to  test  for  a  differential  effect  of  drug
lasses  [7].  On  the  other  hand,  renin-angiotensin  system
nhibitors  usually  decrease  natriuretic  peptide  concentra-
ions,  as  do  diuretics  or  any  drug  that  tends  to  lower  blood
olume  [30]. This  was  conﬁrmed  in  the  LIFE  substudy,  as
T-proBNP  levels  decreased  in  the  group  treated  with  losar-
an  but  increased  in  the  group  treated  with  atenolol  [31].
408  
Figure 4. Survival curves relative to three terciles of plasma NT-
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RroBNP concentrations (n = 684). Modiﬁed from [7].  BNP: B-type
atriuretic peptide; NT: N-terminal.
he  explanation  is  not,  however,  unique.  While  a  direct
ffect  of  angiotensin  II  on  natriuretic  peptide  synthesis
an  be  advocated,  there  is  a  case  for  a  better  haemo-
ynamic  proﬁle  characterized  by  a  decrease  in  vascular
esistances  leading  to  decreased  left  ventricular  afterload
nd  circumferential  wall  stress.  In  any  case,  natriuretic  pep-
ides  (ANP  and  NT-proBNP)  kept  their  prognostic  value  with
oth  beta-blockers  and  angiotensin  II  antagonists,  which
s  of  utmost  importance  in  proposing  these  markers  for
arge-scale  screening  in  hypertension.  A  slight  difference  in
rognostic  cutoff  according  to  ongoing  treatments  cannot
e  ruled  out.  Yet  this  difference,  if  any,  would  be  expected
o  be  very  small,  as  suggested  by  the  small  but  signiﬁcant
bsolute  differences  in  NT-proBNP  concentrations  between
he  two  treatment  groups  in  the  LIFE  substudy  [31].
Concerning  the  second  aspect,  the  fact  that,  in  the  same
tudy,  the  concentrations  of  NT-proBNP  under  treatment
ere  on  average  more  predictive  than  the  basal  concen-
rations  also  suggests  that  it  could  be  used  as  a  surrogate
riterion  for  treatment  adjustment,  with  the  aim  of  decreas-
ng  NT-proBNP  concentration  together  with  lowering  blood
ressure;  this  strategy  is  already  well  accepted  in  the  man-
gement  of  heart  failure  patients.  In  view  of  the  difﬁculties
n  precisely  measuring  blood  pressure  and  the  fact  that,  on
verage,  the  effect  of  antihypertensive  drugs  on  blood  pres-
ure  is  smaller  than  spontaneous  ﬂuctuations,  it  would  be  of
reat  value  for  the  physician  to  be  able  to  adjust  therapy  on
he  basis  of  a  more  stable  surrogate  marker  in  hypertension
ollow-up.  Of  course,  this  deserves  further  study  to  com-
are  the  gain  of  targeting  NT-proBNP  over  blood  pressure
n  terms  of  morbi-mortality,  compared  with  blood  pressure
nly.  Lessons  from  heart  failure  treatment  should  help  to
dentify  the  therapeutic  strategies  that  can  decrease  both
lood  pressure  and  NT-proBNP  plasma  concentrations.G.  Bricca,  P.  Lantelme
onclusions
he  history  of  natriuretic  peptides  in  blood  pressure  reg-
lation,  water,  and  salt  homeostasis  continues  and  new
pplications  are  regularly  reported.  Natriuretic  peptides  are
ariably  elevated  in  hypertension,  reﬂecting  various  degrees
f  cardiac,  vascular,  and  renal  injuries.  The  potential  of  this
arker  to  detect  one  particular  aspect  of  cardiac  remod-
lling  (namely  LVH)  may  be  suboptimal  and  not  sufﬁcient
o  be  proposed  for  large-scale  screening  of  hypertensive
atients,  contrary  to  what  has  been  suggested  earlier.  This
ight  not  be  the  major  point,  however,  as  what  we  critically
eed  is  a  marker  that  can  predict  events  rather  than  organ
amage.  Here,  the  picture  is  totally  different,  as  we  and
thers  have  reported  a strong  predictive  value  for  hard  end-
oints  such  as  all-cause  death  or  cardiovascular  mortality
nd  morbidity.  In  our  view,  it  is  not  a tool  to  replace  echocar-
iography,  which  will  still  have  to  be  performed  to  gain
nsights  into  the  components  of  heart  remodelling.  On  the
ther  hand,  systematic  use  of  echocardiography,  which  is  not
ecommended,  would  be  neither  feasible  nor  desirable  on  an
conomic  basis  [32]. On  the  contrary,  it  could  replace  ECG  in
eneral  practice.  Considering  NT-proBNP,  we  have  reported
hat  it  adds  signiﬁcant  prognostic  information  to  the  con-
entional  Framingham-type  risk  factors  and,  in  our  hands,
erformed  better  than  ECG.  In  addition,  it  may  be  extended
o  all  patients  more  easily  than  ECG.  Furthermore,  it  was
ot  sensitive  to  renal  impairment  or  body  mass  index.  On  the
asis  of  the  literature,  a reasonable  concentration  thresh-
ld  would  be  around  130  pg/mL.  Despite  similar  prognostic
apabilities  in  men  and  women,  the  usefulness  of  different
hresholds  cannot  be  excluded,  as  previously  suggested  for
he  diagnosis  of  LVH  [12].
This  performance,  together  with  the  ease  of  measure-
ent,  low  cost  and  widespread  availability,  should  prompt
ide  use  of  this  marker  for  risk  stratiﬁcation  in  hyperten-
ion  in  most  hypertensive  patients.  Of  course,  the  economic
mpact  of  implementing  this  measurement  in  the  man-
gement  of  the  hypertensive  patient  in  general  should  be
valuated.
New  questions  are  also  raised,  such  as  the  potential  inter-
st  of  these  markers  as  surrogates  to  optimize  therapeutic
trategies;  this  deserves  further  work.
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